Peter Andre works up a sweat in tiny vest as he launches his fitness channel after 34 years in the gym

PETER Andre has launched his first ever online fitness classes after 34 years of training in the gym.

The 47-year-old stripped off to a tiny vest as he revealed his new exciting venture called Get Fit With Peter Andre.

Peter Andre has launched his first ever series of online home workouts


Peter Andre has launched his first ever series of online home workouts

A source exclusively told The Sun: “Peter has wanted to do something with health and fitness for such a long time and now tonight he’s launching his first fitness video!

“It’s free to subscribe so join in and start your fitness journey!”

The first video is a 10 minute HIIT workout that can easily be done at home without any equipment.

Speaking from his home gym, Peter tells fans: “It’s great to finally do this, I’ve been training since I was 13 years old, I’m 47 now.

Pete has always had an impressive physique and has been working out since he was 13


Pete has always had an impressive physique and has been working out since he was 13Credit: Getty Images – Getty

“I’ve gone through so many different stages of training where I did all the weight training, watched everything I ate and was kind of bulky.

“Then I did the other ones where I was just cardio based and I was really shredded and then as time went on I found all the different things I liked – a combination of everything.

“What I want to do in these videos is show you all the different things you can do.

“So if you’re at home and you have no equipment I’m going to give you 10 minute little HIIT training.”

The first video is available to watch on Peter’s YouTube channel and there will be a new workout added every Monday.

Last week, Peter delighted fans by stripping naked to sing his hit Mysterious Girl in the shower.

He sizzled in a video shared with his 1.6 million Instagram followers – 25 years after he first released Mysterious Girl.

Peter Andre left fans swooning when he sang Mysterious Girl in the shower tonight


Peter Andre left fans swooning when he sang Mysterious Girl in the shower tonight

Peter crooned the track from his second studio album, Natural, and showed off the incredible abs that helped make him famous.

He captioned the TikTok video: “They dared me to do it and I was like ‘hell yeah’ 🐠🏝🌴 #mysteriousgirl @tiktok #backtothemusic”

Fans didn’t complain, as Paddy McGuinness’s wife Christine commented: “Yeeessssss 👏😂”

Another said: “Excellent, loved that song 😊”

The 47-year-old released the track 25 years ago


The 47-year-old released the track 25 years ago

Pete’s debut single Drive Me Crazy, released in 1992, peaked at number 72 in the Australian charts

But he became a huge hit when his tracks Mysterious Girl and Flava went global.

Peter reminded fans of his former glory last week, sharing a 90s throwback snap of himself when he was just 21-years-old.

Peter Andre took to his social media to share the picture with fans


Peter Andre took to his social media to share the picture with fansCredit: Instagram/PeterAndre

In the snap a baby faced Pete can be seen rocking a bandana in his hair, an opened checkered shirt and a necklace hanging around his neck.


Read more

Virginia Beach fitness celebrity works passion into every endeavor

Fitness model. Hybrid athlete. Entrepreneur. Mother.

Ashley Horner, 36, wears many different hats, and with them all one thing is consistent: her passion.

And add one other hat, philanthropist, for the woman who ran for 40 hours straight one weekend this month to raise money for an orphanage in Haiti.

Horner grew up on a ranch in Oklahoma and relocated to Virginia Beach five years ago.

“I always had an athletic background with gymnastics and playing soccer when I was younger,” Horner said. To satisfy her competitive nature, Horner got into fitness competitions, including ultra-events, which led to her modeling career.

“I just kept wanting to find something else that would challenge me,” she said.

But, through each professional experience — fitness celebrity, magazine covers, endorsement deals, and dealing with her finances — Horner said she was eager to dig deeper.

Horner is the mother of three sons, Tripp, 13, Cash, 11, and Otto, 5, runs three businesses and has a nonprofit organization.

She opened American Brew on Shore Drive in Virginia Beach in 2016, and relocated the coffee/whiskey bar and restaurant a year later to its current location on East Stratford Road, which is off Shore Drive near the Lynnhaven Inlet.

“I didn’t know anything about the restaurant industry. I’ve had to learn as I continued on,” Horner said. “It’s been a lot of fun and I’m actually looking to open up my second location early in 2021.”

Although times have been tough during the pandemic, Horner said that when it hit she quickly reevaluated the business’s operation system and kept the doors open.

“I knew that my staff depended on me for their income,” she said. “Within a matter of four days we flip-flopped operations. I did whatever I had to do to keep American Brew open.”

The restaurant’s team of 10 rallied and continues to thrive in the community-focused business.

“You talk about overcoming adversity — which is what I’m all about — they really did that and they did an outstanding job,” Horner said.

She also owns and operates Valkyrie Surf and Snow, a small online clothing company she opened in 2016 dedicated to the active female.

With two employees handling the sales, Horner said she might eventually move it to a brick-and-mortar business.

“My overall mission is to empower women. I think it’s really important for women to find beauty and strength within themselves,” she said.

Horner opened American Screen Printing in 2018 purely because she decided she wanted to eliminate the “middleman” and print her apparel herself.

Originally focused on printing for her companies, projects and events, the business has seen rapid growth and now prints for others in town.

She is getting ready to move the business to the Railroad District in Norfolk and will be hiring several more employees.

Eager to help others, Horner started the Unbroken Foundation in 2013. The organization helps battered women and children through its donation-based program.

In July, she started recording her own podcast, “Reborn.” The

Read more

3 Reasons Pfizer And BioNTech’s Coronavirus Vaccine Might Fail Even If It Works

Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) are on the cusp of producing phase 3 data that could show their coronavirus vaccine, BNT162, protects participants from developing COVID-19 better than placebo. But investors should be aware that there are some caveats that could result in a negative clinical trial even if the vaccine actually helps patients.

1. Early infection

The clinical trial starts classifying patients as positive for COVID-19 if the test occurs seven days after the second and final dose of the vaccine. Pfizer and BioNTech set the measurement based on the formation of antibodies in participants enrolled in earlier-stage studies, but if it takes longer to fully protect participants, some of the participants who received the vaccine could become infected between Day 7 and when the participant is truly protected, which would reduce the perceived effectiveness of the vaccine.

2. Virus in the nose

The vaccine is designed to create antibodies that can bind and inhibit the coronavirus once it enters the bloodstream. But the tests for COVID-19 look for the virus in patients’ noses.

Participants in the study could be protected from the coronavirus, but still test positive for COVID-19 because the immune system doesn’t wipe out the virus in the nose and upper respiratory tract where the test sample is taken.

It’s possible that a participant might end up being exposed to the virus, not end up developing COVID-19, but still, be counted as a positive case based on the detection of the virus in the patient’s nose.

3. False-positive testing

COVID-19 tests aren’t 100% accurate. A study of 90 patients who were tested with a COVID-19 test developed by Danaher’s (NYSE:DHR) Cepheid unit, which is being used in Pfizer and BioNTech’s study, produced two false-positive results.

Pfizer and BioNTech’s study also requires patients to have at least one symptom within four days before or after the positive test to be counted as a positive COVID-19 case, but many of the symptoms, including fever, cough, sore throat, diarrhea, and others, are associated with other more benign diseases.

With 21,000 volunteers in the study having received the vaccine, it’s easy to imagine that there might be a few participants who get a false positive test and also have one of those rather benign symptoms.

Hard to handicap

While all three issues are theoretically possible, it’s hard to determine how much they’ll end up affecting the patients who received the vaccine in the clinical trial. Unfortunately, even a small effect could sway the results, considering that the early study results hinge on very small numbers.

The first interim analysis, for example, comes after just 32 people in the study who have developed COVID-19. If six or fewer cases come from the group who received the vaccine, the study will be deemed a success, but a single false positive positive person in the group could push the analysis beyond the success criteria.

Of course, it’s equally likely that the three issues will result in a false positive in the placebo group,

Read more

Alabama statewide school COVID tracker to debut Oct. 30; Here’s how it works

Alabamians anxious to get a look at the prevalence of COVID-19 among students, teachers, and staff in schools statewide will get their chance on Friday.

The dashboard, in the works since late August, will be published on the Alabama Department of Public Health website and will include the number of self-reported positive COVID-19 cases in each school system, but will not be broken down by school.

After discussion between Alabama State Department of Education officials during a Monday afternoon training session for school nurses about whether to report only laboratory-confirmed COVID-19 cases or whether to report all known self-reported positives among students and faculty, Alabama State Superintendent Eric Mackey told the school tracker will follow the same reporting protocol school nurses follow now on the ADPH report card.

“The (Alabama Department of Public Health) school dashboard will use the same protocols for reporting as the ADPH report card,” Mackey wrote to

Currently, the ADPH report card—the mechanism through which school nurses report positive cases to ADPH for contact tracing—does not require laboratory confirmation of positive cases.

Schools currently rely on parents and staff to report positive cases of COVID-19, but schools are not required to collect laboratory results before reporting a positive case.

K-12 schools have not appeared to be the source of community spread of coronavirus, something many feared prior to the opening of schools in August. The school tracker, Mackey said earlier this month, is important for two reasons, Mackey said: “So people take it seriously, and so they don’t overreact.”

“We want to be fully transparent so that people know that there are cases in the community,” Mackey said. Knowing the level of spread, he added, helps people to continue to do the things needed to mitigate that spread.

The school tracker will include positive cases for the week ending each Tuesday evening, officials said. State department of education nurses will review the data, and it will be published online by 10 a.m. each Friday morning.

A school district’s lead nurse is the only school official who can complete the school tracker report for the district, and while student and faculty cases will be reported separately, only a total will be reported to the public. Five cases or fewer will not be reported by number for privacy reasons, officials said.

While there is no national template or standard for reporting cases in schools, some states provide a more detailed breakdown than Alabama is planning to report.

Florida reports positive cases by school and whether the person is a student, teacher, or other staff member. Their report also includes whether persons were showing symptoms. Louisiana reports cases weekly but only by parish, or county. Utah breaks case data down into three age groups, 5 to 10 years old, 11 to 13 years old and 14 to 18 years old.

For its school reporting dashboard, New York’s public health department not only relies on self-reporting, but also uses official lab results, matching the lab results to the

Read more

This Addiction Treatment Works. Why Is It So Underused?

“In the drawings, I did pretty good,” said Eric Alick, 63, of Philadelphia, who completed a contingency management program for cocaine addition at the Corporal Michael J. Crescenz V.A. Medical Center in Pennsylvania. “I might get three ‘good jobs’ in a row, but then, bingo.”

Among the things he bought with his rewards were a new drill set for his job as a handyman, perfume for his wife and coffee and meals for homeless veterans whom he had met in the hospital cafeteria.

One problem with contingency management, evidence suggests, is that people have less success staying abstinent after the treatment ends. For that reason, Richard Rawson, a researcher at the University of Vermont who has studied meth addiction for decades, believes it should be used indefinitely, just as medications for opioid addiction often are.

“Unfortunately, addiction is a chronic brain disease and treatments need to be designed to accommodate this reality,” he said.

For Ms. Waxler-Malloy, losing the debit card when her four months of contingency management ended in early January was hard, although her therapy sessions and 12-step meetings helped. Then, in May, she lost her waitressing job because of the pandemic and she relapsed, using meth and heroin “full force,” she said, for three weeks before stopping with help from Brightview.

Still, the eight months she went without using drugs was her longest stretch of abstinence in more than two decades. She believes she may not have relapsed if contingency management, with its promise of rewards, had still been part of her treatment regimen.

“That kept me real accountable,” she said recently. “Even just to stop at McDonald’s when you have that little bit of extra money, to get a hamburger and a fries when you’re hungry. That was really big to me.”

Source Article

Read more

Trump said that he is “cured” of COVID-19. Scientists say that’s not how it works

Donald Trump
Donald Trump

U.S. President Donald Trump debates Democratic presidential nominee Joe Biden at Belmont University on October 22, 2020 in Nashville, Tennessee. This is the last debate between the two candidates before the November 3 election. Jim Bourg-Pool/Getty Images

This article originally appeared here on

In a night full of many bold claims made by President Trump, one stood out to immunologists: Trump’s statement, during the Thursday night debate with Joe Biden, that he had been “cured” of COVID-19. 

“I can tell you from personal experience that I was in the hospital, I had it,” Trump claimed. “And I got better and I will tell you that I had something that they gave me — a therapeutic, I guess they would call it. Some people could say it was a cure. But I was in for a short period of time and I got better very fast or I wouldn’t be here tonight. And now they say I’m immune. Whether it’s four months or a lifetime, nobody’s been able to say that, but I’m immune.”

The only problem? Immunity doesn’t work that way, experts say. And there are other reasons to take Trump’s comments with a grain of salt, too.

“There is no cure for this disease,” Dr. Georges Benjamin, executive director of the American Public Health Association (APHA) and former secretary of health in Maryland, wrote to Salon. “The treatments are very limited and reduce the severity of the disease in a subset of patients. So this is inaccurate.”

Related Articles

He added, “He may be immune but we don’t know for sure. More importantly, if he is, we don’t know for how long he will have protections. [The] current thinking is a few months, but studies are ongoing to find out how long. Reinfections are very rare so far which argues for immunity. Remember the disease is less than a year old so we don’t yet know it’s long term course.”

Benjamin was referring to a host of new research that indicates that immunity is only temporary for the virus — in scientific speak, immunity is not “durable.” A Nature Medicine article suggested that those who contract the novel coronavirus and recover may be immune to it for about twelve months. There are reported cases around the world of some becoming re-infected after three months. 

Dr. Russell Medford, Chairman of the Center for Global Health Innovation and Global Health Crisis Coordination Center, reacted to Trump’s claim of having been cured by writing to Salon that “the President’s clinical course with COVID-19 is a single case study.  None of the therapies the President received have been demonstrated to be ‘cures’ in clinical trials that test hundreds or thousands of patients infected with the SARS-CoV-2 virus. Indeed, only a handful of patients outside of clinical trials have received Regeneron’s monoclonal antibody.”

Regarding Trump’s claim of being immune, he was skeptical that he could even know that. “As a new disease, our understanding of the body’s immune response

Read more

TAVR in Degenerated TAVR Valve Works in ‘No Option’ Patients

When a surgical aortic valve prosthesis degenerates, the patient— older, perhaps sicker, and no longer a good candidate for surgery — has a valve-in-valve alternative in the form of transcatheter aortic valve replacement (TAVR). But it’s been unclear whether a second TAVR can be an effective fix for patients with aged, failing TAVR valves.

Such “TAVR in TAVR” indeed can be successful with relative safety, suggests a small registry study of patients with failed transcatheter valves who had been at intermediate to high surgical risk when they underwent their first procedure 3 to 4 years earlier. All were thought to have exhausted other good treatment options and so had been offered a second TAVR.

Luca Testa

The early findings from the TRANSIT registry, which includes some patients who were among the earliest to receive TAVR valves, should be “quite reassuring for both patients and physicians,” Luca Testa, MD, told | Medscape Cardiology.

For such patients and candidates for the procedure today, regardless of their surgical risk, the results “support the concept that a degenerated TAVR can be safely and successfully treated by means of a second TAVR,” said Testa, from the Institute of Hospitalization and Scientific Care, San Donato Polyclinic, Milan.

Testa presented the TRANSIT registry analysis October 17 during TCT Connect, the virtual edition of Transcatheter Cardiovascular Therapeutics (TCT) 2020.

The study included all 172 patients who underwent TAVR for a degenerated TAVR valve at 28 mostly European centers from 2008 to this year, out of the approximately 40,000 primary TAVRs performed at those institutions. None of the new procedures were to treat TAVR valves that had failed acutely at implantation.

All patients were considered to be at intermediate to high surgical risk at their first TAVR, and all were at high surgical risk at the time of their second TAVR, with a mean age of 80 years, about 70% with NYHA class 3 to 4 heart failure, and prevalent renal disease. By then, medical therapy wasn’t effective “and surgery had been rejected years before,” Testa said.

The transfemoral approach was used in 92%, and only about 10% of the second procedures involved a transcatheter cerebral protection device.

The degenerated valves were overwhelmingly Corevalve Evolut R (Medtronic) and Sapien XT (Edwards Lifesciences) devices, which were by far the dominant TAVR valves used during the years covered by the analysis, Testa pointed out.

“The numbers of patients having a degenerated TAVR valve will increase steadily every year,” he said. In the years since the TRANSIT patients received their first TAVR, the procedure has extended to a wide spectrum of patients almost regardless of their suitability for surgical aortic valve replacement (SAVR) based on operative risk.

That means “we will be even more often treating patients who are low risk, in their 60s and 70s, who have a high chance of outliving their bioprosthesis,” Testa said. Now, there is evidence physicians can show patients that if a first TAVR fails “in the next 10 years, for example, we can

Read more
  • Partner links